Preventable statin adverse reactions and therapy discontinuation. What can we learn from the spontaneous reporting system?

References

• Agabiti Rosei E, Salvetti M. Management of hypercholesterolemia, appropriateness of therapeutic approaches and new drugs in patients with high cardiovascular risk. High Blood Press Cardiovasc Prev. 2016;23(3):217–230.
   PubMed Web of Science ®Google Scholar
• Sathasivam S. Statin induced myotoxicity. Eur J Intern Med. 2012;23(4):317–324.
   PubMed Web of Science ®Google Scholar
• Tiwari A, Bansal V, Chugh A, et al. Statins and myotoxicity: a therapeutic limitation. Expert Opin Drug Saf. 2006;5:651–666.
   PubMed Web of Science ®Google Scholar
• Chatzizisis YS, Koskinas KC, Misirli G, et al. Risk factors and drug interactions predisposing to statin-induced myopathy: implications for risk assessment, prevention and treatment. Drug Saf. 2010;33(3):171–187.
   PubMed Web of Science ®Google Scholar
• Schech S, Graham D, Staffa J, et al. Risk factors for statin-associated rhabdomyolysis. Pharmacoepidemiol Drug Saf. 2007;16(3):352–358.
   PubMed Web of Science ®Google Scholar
• Lemstra M, Blackburn D, Crawley A, et al. Proportion and risk indicators of nonadherence to statin therapy: a meta-analysis. Can J Cardiol. 2012;28:574–580.
   PubMed Web of Science ®Google Scholar
• Mann DM, Woodward M, Muntner P, et al. Predictors of nonadherence to statins: a systematic review and meta-analysis. Ann Pharmacother. 2010;44:1410–1421.
   PubMed Web of Science ®Google Scholar
• Sessa M, Sportiello L, Mascolo A, et al. Campania preventability assessment committee (Italy): a focus on the preventability of non-steroidal anti-inflammatory drugs’ adverse drug reactions. Front Pharmacol. 2017;8:305.
   PubMed Web of Science ®Google Scholar
• Sessa M, Rossi C, Rafaniello C, et al. Campania preventability assessment committee: a focus on the preventability of the contrast media adverse drug reactions. Expert Opin Drug Saf. 2016;15:51–59.
   PubMed Web of Science ®Google Scholar
• Sessa M, Rafaniello C, Sportiello L, et al. Campania region (Italy) spontaneous reporting system and preventability assessment through a case-by-case approach: a pilot study on psychotropic drugs. Expert Opin Drug Saf. 2016;15:9–15.
   PubMed Web of Science ®Google Scholar
• Illario M, Vollenbroek-Hutten M, Molloy DW, et al. Active and healthy ageing and independent living. J Aging Res. 2015;2015:542183.
   PubMedGoogle Scholar
• Cammarota S, Bruzzese D, Catapano AL, et al. Lower incidence of macrovascular complications in patients on insulin glargine versus those on basal human insulins: a population-based cohort study in Italy. Nutr Metab Cardiovasc Dis. 2014;24(1):10–17.
   PubMed Web of Science ®Google Scholar
• Casula M, Catapano AL, Piccinelli R, et al. Assessment and potential determinants of compliance and persistence to antiosteoporosis therapy in Italy. Am J Manag Care. 2014;20(5):e138–45.
   PubMed Web of Science ®Google Scholar
• Pal SN, Olsson S, Brown EG. The monitoring medicines project: a multinational pharmacovigilance and public health project. Drug Saf. 2015;38:319–328.
   PubMed Web of Science ®Google Scholar
• Benkirane R, Soulaymani-Bencheikh R, Khattabi A, et al. Assessment of a new instrument for detecting preventable adverse drug reactions. Drug Saf. 2015;38:383–393.
   PubMed Web of Science ®Google Scholar
• Brown EG, Wood L, Wood S. The medical dictionary for regulatory activities (MedDRA). Drug Saf. 1999;20:109–117.
   PubMed Web of Science ®Google Scholar
• International Conference on Harmonisation E2D. Post-Approval safety data management: definitions and standards for expedited reporting [Internet]. [cited 2016 Apr 4]. Available from: http://www.emea.eu.int/pdfs/human/ich/394503en.pdf.
   Google Scholar
• Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239–245.
   PubMed Web of Science ®Google Scholar
• European Medicine Agency. Important medical event terms (IME) list. United Kingdom [Internet]. 2017. Available from: https://eudravigilance.ema.europa.eu/human/textforIME.asp.
   Google Scholar
• Burtis CA, Ashwood ER, Bruns DE. Tietz textbook of clinical chemistry and molecular diagnostics-e-book. India: Elsevier Health Sciences; 2012.
   Google Scholar
• Sessa M, Rossi C, Mascolo A, et al. Suspected adverse reactions to contrast media in Campania region (Italy): results from 14 years of post-marketing surveillance. Expert Opin Drug Saf. 2015;14:1341–1351.
   PubMed Web of Science ®Google Scholar
• Mascolo A, Sessa M, Scavone C, et al. New and old roles of the peripheral and brain renin-angiotensin-aldosterone system (RAAS): focus on cardiovascular and neurological diseases. Int J Cardiol. 2017;227:734–742.
   PubMed Web of Science ®Google Scholar
• Scavone C, Sportiello L, Rafaniello C, et al. New era in treatment options of chronic hepatitis C: focus on safety of new direct-acting antivirals (DAAs). Expert Opin Drug Saf. 2016;85–100.
   PubMed Web of Science ®Google Scholar
• Sessa M, Mascolo A, Andersen MP, et al. Effect of chronic kidney diseases on mortality among digoxin users treated for non-valvular atrial fibrillation: a nationwide register-based retrospective cohort study. PLoS One. 2016;11(7):e0160337.
   PubMed Web of Science ®Google Scholar
• Sessa M, Sullo MG, Mascolo A, et al. A case of figurate urticaria by etanercept. J Pharmacol Pharmacother. 2016;7:106–108.
   PubMed Web of Science ®Google Scholar
• Rafaniello C, Ferrajolo C, Sullo MG, et al. Risk of gastrointestinal complications associated to NSAIDs, low-dose aspirin and their combinations: results of a pharmacovigilance reporting system. Pharmacol Res. 2016;104:108–114.
   PubMed Web of Science ®Google Scholar
• Mascolo A, Scavone C, Sessa M, et al. Can causality assessment fulfill the new European definition of adverse drug reaction? A review of methods used in spontaneous reporting. Pharmacol Res. 2017;123:122–129.
   PubMed Web of Science ®Google Scholar
• Parretta E, Rafaniello C, Magro L, et al. Improvement of patient adverse drug reaction reporting through a community pharmacist-based intervention in the Campania region of Italy. Expert Opin Drug Saf. 2014;13(Suppl 1):S21–9.
   PubMed Web of Science ®Google Scholar
• Scavone C, Sportiello L, Sullo MG, et al. Safety profile of anticancer and immune-modulating biotech drugs used in a real world setting in Campania Region (Italy): BIO-Cam observational study. Front Pharmacol. 2017;8:607.
   PubMed Web of Science ®Google Scholar
• Mascolo A, Rafaniello C, Sportiello L, et al. Dipeptidyl Peptidase (DPP)-4 inhibitor-induced Arthritis/Arthralgia: a review of clinical cases. Drug Saf. 2016;39(5):401–407.
   PubMed Web of Science ®Google Scholar
• Mo L, He J, Yue Q, et al. Increased dosage of cyclosporine induces myopathy with increased seru creatine kinase in an elderly patient on chronic statin therapy. J Clin Pharm Ther. 2015;40:245–248.
   PubMed Web of Science ®Google Scholar
• Tafreshi MJ, Zagnoni LG, Gentry EJ. Combination of clopidogrel and statins: a hypothetical interaction or therapeutic dilemma? Pharmacotherapy. 2006;26(3):388–394.
   PubMed Web of Science ®Google Scholar
• Bhindi R, Ormerod O, Newton J, et al. Interaction between statins and clopidogrel: is there anything clinically relevant? Qjm. 2008;101(12):915–925.
   PubMed Web of Science ®Google Scholar
• Bjornsson E, Jacobsen EI, Kalaitzakis E. Hepatotoxicity associated with statins: reports of idiosyncratic liver injury post-marketing. J Hepatol. 2012;56:374–380.
   PubMed Web of Science ®Google Scholar
• Reuben A, Koch DG, Lee WM. Drug-induced acute liver failure: results of a U.S. multicenter, prospective study. Hepatology. 2010;52:2065–2076.
   PubMed Web of Science ®Google Scholar
• Russo MW, Scobey M, Bonkovsky HL. Drug-induced liver injury associated with statins. Semin Liver Dis. 2009;29:412–422.
   PubMed Web of Science ®Google Scholar
• Degli Esposti L, Saragoni S, Sangiorgi D, et al. The nationwide osmed health-Db database. A tool to support healthcare decision-making and real-world evidence generation. Value Health. 2015;18:A693.
   PubMed Web of Science ®Google Scholar
• Ferrajolo C, Arcoraci V, Sullo MG, et al. Pattern of statin use in southern italian primary care: can prescription databases be used for monitoring long-term adherence to the treatment? PLoS One. 2014;9:e102146.
   PubMed Web of Science ®Google Scholar
• Poluzzi E, Piccinni C, Carta P, et al. Cardiovascular events in statin recipients: impact of adherence to treatment in a 3-year record linkage study. Eur J Clin Pharmacol. 2011;67:407–414.
   PubMed Web of Science ®Google Scholar
• Corrao G, Scotti L, Zambon A, et al. Cost-effectiveness of enhancing adherence to therapy with statins in the setting of primary cardiovascular prevention. Evidence from an empirical approach based on administrative databases. Atherosclerosis. 2011;217:479–485.
   PubMed Web of Science ®Google Scholar
• Degli Esposti L, Saragoni S, Batacchi P, et al. Adherence to statin treatment and health outcomes in an Italian cohort of newly treated patients: results from an administrative database analysis. Clin Ther. 2012;34:190–199.
   PubMed Web of Science ®Google Scholar
• Casula M, Tragni E, Piccinelli R, et al. A simple informative intervention in primary care increases statin adherence. Eur J Clin Pharmacol. 2016;72:227–234.
   PubMed Web of Science ®Google Scholar
• Monaldi B, Bologna G, Costa GG, et al. Adherence to statin treatment following a myocardial infarction: an Italian population-based survey. Clinicoecon Outcomes Res. 2015;7:273–280.
   PubMed Web of Science ®Google Scholar
• Guglielmi V, Bellia A, Pecchioli S, et al. Effectiveness of adherence to lipid lowering therapy on LDL-cholesterol in patients with very high cardiovascular risk: a real-world evidence study in primary care. Atherosclerosis. 2017;263:36–41.
   PubMed Web of Science ®Google Scholar
• Leporini C, Degli Esposti L, Sangiorgi D, et al. Adverse drug reactions, medication adherence and physicians’ prescribing behavior: which relationship? A database analysis on statin use. Value Health. 2015;18(7):A374.
   PubMed Web of Science ®Google Scholar
• Mancini GBJ, Tashakkor AY, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian working group consensus update. Can J Cardiol. 2013;29:1553–1568.
   PubMed Web of Science ®Google Scholar
• Laufs U, Filipiak KJ, Gouni-Berthold I, et al. Practical aspects in the management of statin-associated muscle symptoms (SAMS). Atheroscler Suppl. 2017;26:45–55.
   PubMed Web of Science ®Google Scholar
• Roth GA, Johnson C, Abajobir A, et al. Global, regional, and national burden of cardiovascular diseases for 10 causes, 1990 to 2015. J Am Coll Cardiol. 2017;70(1):1–25.
   PubMed Web of Science ®Google Scholar